Biofourmis, a Boston company specializing in digital therapeutics, is acquiring Biovotion AG from Zurich. Biovotion develops wearable devices to measure health data. Their lead product is the biosensor Everion, which is worn on the arm and capable of measuring 22 clinical and non-clinical parameters in real time, such as heart rate, respiratory rate, blood oxygenation and skin temperature.
The acquisition comprises all Biovotion’s assets, including more than 60 global patents covering “most of the wearable and sensor technology that exists for the arm or hand”, according to a statement. The American company plans to combine data gathered by Biovotion’s wearables with its digital therapeutics platform so the artificial intelligence-driven platform can provide more precise treatment options for users’ illnesses.
The entire Biovotion team will be incorporated into Biofourmis, writes the statement. Operating under the new name Biofourmis AG, the company will maintain its Zurich headquarters.